EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study

Stefano Partelli iD, Luca Landoni, Mirco Bartolomei, Alessandro Zerbi, Chiara Maria Grana, Ugo Boggi, Giovanni Butturini, Riccardo Casadei, Roberto Salvia, Massimo Falconi

British Journal of Surgery · 2024

DOI: 10.1093/bjs/znae178 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Stefano Partelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Octreotide, Organometallic Compounds. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Advanced Accelerator Applications.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resection of non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) is curative in most patients. The potential benefits of neoadjuvant treatments have, however, never been explored. The primary aim of this study was to evaluate the safety of neoadjuvant 177Lu-labelled DOTA0-octreotate (177Lu-DOTATATE) followed by surgery in patients with NF-PanNETs.

Methods

NEOLUPANET was a multicentre, single-arm, phase II trial of patients with sporadic, resectable or potentially resectable NF-PanNETs at high-risk of recurrence; those with positive 68Ga-labelled DOTA PET were eligible. All patients were candidates for neoadjuvant 177Lu-DOTATATE followed by surgery. A sample size of 30 patients was calculated to test postoperative complication rates against predefined cut-offs. The primary endpoint was safety, reflected by postoperative morbidity and mortality within 90 days. Secondary endpoints included rate of objective radiological response and quality of life.

Results

From March 2020 to February 2023, 31 patients were enrolled, of whom 26 completed 4 cycles of 177Lu-DOTATATE. A partial radiological response was observed in 18 of 31 patients, and 13 patients had stable disease. Disease progression was not observed. Twenty-four R0 resections and 4 R1 resections were performed in 29 patients who underwent surgery. One tumour was unresectable owing to vascular involvement. There was no postoperative death. Postoperative complications occurred in 21 of 29 patients. Severe complications were observed in seven patients. Quality of life remained stable after 177Lu-DOTATATE and decreased after surgery.

Conclusion

Neoadjuvant treatment with 177Lu-DOTATATE is safe and effective for patients with NF-PanNETs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyOctreotideOrganometallic CompoundsHumansFemaleMaleMiddle AgedAgedAdultNeuroendocrine TumorsRadiopharmaceuticalsQuality of LifePancreatectomy

Substanzen

Octreotidelutetium Lu 177 dotatateOrganometallic CompoundsRadiopharmaceuticals

Autor:innen und Institutionen

  • School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
  • Pancreas Translational and Clinical Research Centre, Pancreatic and Transplant Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.
  • Nuclear Medicine Unit, Oncological Medical and Specialists Department, University Hospital of Ferrara, Ferrara, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Pancreatic Surgery Unit, IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Stefano Partelli

Förderung

  • Advanced Accelerator Applications

Zitieren

APA

Partelli, S., Landoni, L., Bartolomei, M., Zerbi, A., Grana, C. M., Boggi, U., Butturini, G., Casadei, R., Salvia, R., & Falconi, M. (2024). Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. British Journal of Surgery. https://doi.org/10.1093/bjs/znae178

Vancouver

Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U, et al. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. British Journal of Surgery. 2024. doi:10.1093/bjs/znae178

BibTeX
@article{Partelli2024,
  author = {Partelli, Stefano and Landoni, Luca and Bartolomei, Mirco and Zerbi, Alessandro and Grana, Chiara Maria and Boggi, Ugo and Butturini, Giovanni and Casadei, Riccardo and Salvia, Roberto and Falconi, Massimo},
  title = {Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study},
  journal = {British Journal of Surgery},
  year = {2024},
  doi = {10.1093/bjs/znae178}
}
Kostenlos starten →